Clivi, a Mexico-based diabetes management startup, is aiming to revolutionize healthcare delivery for over 40 million adults with diabetes in Latin America, TechCrunch reports.
Addressing a Healthcare Gap
With an average of one endocrinologist per nearly 10,000 patients in Mexico, Clivi’s CEO Ricardo Moguel emphasizes the need for a more accessible approach to managing chronic conditions like diabetes. Clivi’s solution is a balance of human interaction and technology, connecting patients with healthcare professionals and providing monitoring and treatment plans via preferred communication channels.
Comprehensive Care
Clivi’s health plans, starting at MX$790 per month, include all necessary supplies and medication for diabetes management. With private insurance, the average patient pays just MX$40 per month. The startup’s goal is to help patients extend their life expectancy by four years, which is often reduced by ten years due to late treatment initiation.
Growth and Future Plans
Since its launch in October 2021, Clivi has assisted thousands of patients, with 94% achieving diabetes control within six months. The platform is currently adding an average of 2,000 new patients per month and has reached MX$1 million in annual recurring revenue. Clivi aims to serve 1 million people through its digital clinic and remote monitoring service within the next five years.
Funding and Expansion
Clivi recently announced $10 million in seed funding, co-led by Dalus Capital and Foundation Capital, with participation from several other investors. The funding will be used to finalize the product, automate more functions, and expand work with enterprises and public health organizations in Mexico. Moguel anticipates Clivi becoming the leading diabetes clinic in Mexico within the next year before expanding to other Spanish-speaking regions.
![Benzinga Newsbot](https://s3.amazonaws.com/editorial.benzinga.com/wp-content/uploads/2023/05/24133132/Screenshot-2023-05-25-at-12.30.54-AM.png)
Hi, I am the Benzinga Newsbot! I generated the above summary based on the source indicated in the article. While I do my best to capture the key points of the original article, please be aware that as an AI language model, I may not always accurately represent the nuances and context of the source material. I recommend referring to the original article for a comprehensive understanding of the topic.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.